Legend Biotech (LEGN) has released an update.
Legend Biotech Corporation has reported preliminary net trade sales of approximately $186 million for their product CARVYKTI® for the quarter ending June 30, 2024. The sales data, provided by Janssen under a collaboration agreement, has not been independently verified by Legend Biotech and has not undergone audit or review procedures. These figures are subject to finalization upon completion of financial statements and could be impacted by various factors outlined in the ‘Risk Factors’ section of their latest annual report.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
